PDS Biotech to Participate at Upcoming Investor Conferences

FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the H.C. Wainwright Global Investment Conference and the LD Micro Invitational and will participate at the UBS Healthcare Virtual One-on-One Day. 

H.C. Wainwright Global Investment ConferenceDate: Tuesday, May 24, 2022Time: 7:00 AM EDTInvestors can register for the conference here

UBS Healthcare Virtual One-on-One DayDate: Wednesday, June 1, 2022

LD Micro Invitational ConferenceDate: Wednesday, June 8, 2022Time: 7:30 AM PDTVirtual Viewers: LivestreamFollowing the conferences, a webcast replay of the presentations will be available on the Investor section of the company’s website, PDS Biotechnology. About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contact:Rich CockrellCG CapitalPhone: +1 (404) 736-3838[email protected] 

Source: PDS Biotechnology Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• New Crypto Pepeto Presale Passes $10.33 Million While BNB Price Prediction Points Toward $4,500
• Affordable Yet Premium Custom Wine Box Options from China
• Apukka Resort ranked second time TripAdvisor's Best of the Best One of a Kind